Original Source(s)
Related Content
FDA Expands Afrezza to Pediatric Diabetes
The decision was supported by the phase 3 INHALE-1 trial and additional long-term safety, efficacy, and exposure data.
May 29, 2026
-
3 min
Early ICU Rehab Backed, With Caveats
Invited narrative review supports early, interprofessional rehabilitation across the ICU recovery continuum while emphasizing heterogeneous evidence and inconsistent implementation worldwide.
May 11, 2026
-
8 min
Retatrutide Shows 28% Weight Loss in Phase 3 Trial
Nearly half of participants receiving the highest dose achieved at least 30% body weight reduction.
May 21, 2026
-
2 min
